Announcements Trials
Browse Landscape

Phase

Phase 2 178Phase 1 166Phase 1/2 79Phase 3 19Phase NA 18Phase EARLY_PHASE1 8Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Sarcoma 10Osteosarcoma 5Bone Neoplasms 5Neurofibrosarcoma 3Neoplasms 3Lung Neoplasms 3Liposarcoma 3Leiomyosarcoma 3Sarcoma, Synovial 2Sarcoma, Ewing 2Sarcoma, Alveolar Soft Part 2Nerve Sheath Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Histiocytoma, Malignant Fibrous 2Gliosarcoma 2Gastrointestinal Stromal Tumors 2Fibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Urogenital Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Sezary Syndrome 1Sarcoma, Clear Cell 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Temozolomide 2veliparib 1Radiotherapy 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Gliosarcoma × Sarcoma × Clear all
NCT02152982 2026-04-28

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡